Clinical impact of ceruloplasmin levels at ANCA-associated vasculitis diagnosis
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0311678 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Louis Camboulive und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, CHU de Caen Normandie, Caen, France. Hauptthemen laut MEDLINE: Ceruloplasmin, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Peroxidase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Ceruloplasmin is an inhibitor of myeloperoxidase (MPO) activity that plays an important role in the pathophysiology of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). This study aimed to evaluate the prognostic impact of serum level of ceruloplasmin at diagnosis in patients with anti-MPO antibody-positive AAV.
Methods
This retrospective monocentric study in Caen University Hospital involved all consecutive adult anti-MPO antibody-positive patients with microscopic polyangiitis or granulomatosis with polyangiitis, diagnosed between January 2010 and January 2022 with available serum sample at inclusion. Patients outcomes were analyzed from two subgroups constituted according to the median serum level of ceruloplasmin. The same analyses were then performed in anti-proteinase 3 (PR3) antibody-positive patients.
Results
Within the 92 patients analyzed, 50 patients had anti-MPO antibodies with a median ceruloplasmin level of 0.44 [quartiles 1–3, 0.40–0.49] g/L and a median Birmingham Vasculitis Activity Score of 19 [14–22]. After a median follow-up period of 40 [22–86] months, 13 (26%) patients had died: 10 (40%) in the low ceruloplasmin group and 3 (12%) in the high ceruloplasmin group (p = 0.03), with a significantly worse survival rate in the low ceruloplasmin group (p = 0.021). No significant differences in relapse rate or renal failure was observed between the two groups. The same analyses performed in the group of AAV patients with anti-PR3 antibody did not show any differences.
Conclusion
In anti-MPO AAV patients, serum level of ceruloplasmin at diagnosis seems to be associated with a significant impact on survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, CHU de Caen Normandie, Caen, France.
- Laboratoire de Biochimie, CHU de Caen Normandie, Caen, France.
- Laboratoire d'Immunologie et d'Histocompatibilité, CHU de Caen Normandie, Caen, France.
- Department of Nephrology, CHU de Caen Normandie, Caen, France.
- Normandie Univ, UNICAEN, UR4650 PSIR, CHU de Caen Normandie, Caen, France.
ORCID-Profile: Louis Camboulive
Zitieren
APA
Camboulive, L., Grandhomme, F., Martin Silva, N., Khoy, K., Mariotte, D., Lobbedez, T., Dumont, A., Nguyen, A., de Boysson, H., Aouba, A., & Deshayes, S. (2024). Clinical impact of ceruloplasmin levels at ANCA-associated vasculitis diagnosis. PLOS ONE. https://doi.org/10.1371/journal.pone.0311678
Vancouver
Camboulive L, Grandhomme F, Martin Silva N, Khoy K, Mariotte D, Lobbedez T, et al. Clinical impact of ceruloplasmin levels at ANCA-associated vasculitis diagnosis. PLOS ONE. 2024. doi:10.1371/journal.pone.0311678
BibTeX
@article{Camboulive2024,
author = {Camboulive, Louis and Grandhomme, Frédérique and Martin Silva, Nicolas and Khoy, Kathy and Mariotte, Delphine and Lobbedez, Thierry and Dumont, Anaël and Nguyen, Alexandre and de Boysson, Hubert and Aouba, Achille and Deshayes, Samuel},
title = {Clinical impact of ceruloplasmin levels at ANCA-associated vasculitis diagnosis},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0311678}
}
EUVIMED